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with either an untreated existing partner or a new infected partner. [8] Chlamydia reinfection incidence and treatment failure is rising with high repeat C. trachomatis infection rates observed in community cohorts of women in the UK (25.5%) and among women attending general practice clinics in Australia (22.3%) and the UK (29.9%). [10] In the current study, we identified two groups of women (single infection versus repeat infections) and studied their serum antibody response. We aimed to gain insight into why some of the individual women get reinfected with Chlamydia while some of them only have a single infection. The specific aim of the present study was to characterise the systemic antibody responses (IgG and IgA) of these two groups of individuals against semi-purified elementary bodies (EBs) of C. trachomatis serovar D.
MaterIals and Methods

Chlamydia trachomatis cell culture and preparation of semi-purified elementary bodies
C. trachomatis serovar D (ATCC ® VR-885 ™ ) EBs were prepared by infecting HEp-2 cell lines (ATCC ® CCL-23) in the presence of Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Australia) containing 5% heat-inactivated foetal calf serum (FCS) (Life Technologies, Australia), 120 µg/ml streptomycin (Sigma-Aldrich, Australia) and 50 µg/ml gentamycin (Gibco, Australia), 37°C, 5% CO 2 .
Once cells reach confluence (>90%), they were infected with C. trachomatis serovar D EBs in sucrose phosphate buffer (SPG) by centrifugation at 500 ×g at 28°C for 30 min, and afterwards incubated in DMEM containing 2% FCS and cycloheximide (1 µg/ml) to inhibit HEp-2 cell protein synthesis. 48-50 h postinfection, media was removed from the infected flask and replaced with ice-cold SPG. The C. trachomatis-infected monolayer was scraped from the flask and added to the fresh falcon tube containing glass beads (Sigma-Aldrich, Australia) and further vortexed it. The suspension was then centrifuged at 500 ×g for 10 min at 4°C and the supernatant centrifuged at 18,000 ×g for 30 min at 4°C. The semi-purified EB was resuspended in SPG and stored at −80°C. [11] [12] [13] Serial dilutions of the suspension obtained were used for EB quantification. HEp-2 cells were fixed and stained with monoclonal antibody-fluorescein isothiocyanate. The mean number of inclusion-forming units (IFUs) of the single dilutions, counted at the epifluorescence microscope (Leica DMLB), was used to calculate the suspension titre expressed in IFU/ml. [14] [15] [16] 
Chlamydia trachomatis serology
Enzyme-linked immunosorbent assay
Serum IgG and IgA antibody titres for each individual were determined, as described by Carey et al., 2010, [17] at two different time points (for individual with both single infection, as indicated with suffix 3, as well as repeated infection, as indicated with suffix 15) as well as at single time point (for individuals having single infection only as indicated with suffix 3). Two-fold dilutions of serum (50 µl/well) were added to the wells of flat-bottom 96-well plates (ThermoLab systems) coated with semi-purified EBs of C. trachomatis D (5 × 10 4 EBs per well).
Western blot
Western blot assay was used to assess the expression of IgG and IgA antibodies of an individual serum sample specific to C. trachomatis D semi-purified EBs (1.75 × 10 5 ) and was performed as described previously. [18] In brief, ~30 µg of purified EBs was loaded on 0.75 mm-wide 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis gels (110 V for 1 h). Following transfer to a nitrocellulose membrane (Pall Corporation, Australia) at 90 V for 1 h, membranes were blocked for non-specific binding in blocking buffer (5% skimmed milk in 1× Tris-buffered saline) overnight at 4°C or for 2 h at room temperature. For the post-blocking, serum samples were added on to the membrane at a dilution of 1:1000 in blocking buffer and incubated overnight at 4°C or 2 h at room temperature. Membranes were then washed 4 times with 1 × TBS-T for 5 min each. Secondary antibody anti-human IgG and IgA in goat were added at 1:1000 dilutions in blocking buffer and incubated for 1 h at room temperature. Membranes were again washed 4 × with TBS-T for 5 min each. Finally, tertiary antibody (Donkey anti-goat IgG horseradish peroxidase [HRP] conjugate [for IgG detection] and Rabbit anti-goat IgA HRP conjugate [for IgA detection] Southern Biotech/Invitro Technologies, Cleveland, Australia) was separately added onto the membranes at 1:1000 in blocking buffer for 1 h at room temperature. Membranes were then washed 5 × with TBS-T for 5 min each. Blots were visualised for bands by adding enzymatic chemiluminescence substrate (Thermo Fisher Scientific, Australia).
In vitro chlamydia neutralisation assay
In vitro neutralisation assay was performed using individual's serum samples collected at two different time points (individual with single and repeated infection) as well as single time point, according to Kollipara et al. [18] Both cells and inclusions were counted under the microscope, and a mean of ten fields of view for each well was counted and the neutralisation percentage was determined and compared to media-only controls.
Statistical analysis
All statistical analyses were performed using GraphPad Prism version 6 (GraphPad Software, LaJolla, CA, USA). Data were presented as mean ± standard deviation from triplicate assays. For statistical significance, data were analysed using one-way ANOVA and Kruskal-Wallis (nonparametric) tests. The P value for significance was set at ≤0.05.
results
In the present study, the serum samples were obtained from a cohort (n = 22) of women (enrolled in the Australian Chlamydia Treatment Study, ACTS), infected with different Chlamydia serovars. Out of these 22 individuals, five women were infected with serovar D, one was infected with serovar K, 12 were infected with serovar E and four were infected with serovar F. The systemic antibody response (IgG and IgA) was measured via enzyme-linked immunosorbent assay (further validated through Western blot) among the individuals (i.e., homologous vs. homologous and homologous vs. heterologous) having single as well as those having repeated infections. Further, the neutralising ability of different serum samples (infected with different Chlamydia serovar) was analysed against semi-purified EBs of C. trachomatis serovar D.
Systemic antibody responses of patients infected with Chlamydia trachomatis serovar D or K showed correlations with reinfection risk
The results showed that some of the individuals (40%) infected with serovar D exhibited high IgG and IgA antibody titres [1-020-3, 1-186-3, Figure 1a ] as well as exhibiting high neutralisation level in the in vitro assay [ Figure 1c ]. Hence, we propose that they may have had some level of protection against reinfection; patient 1-193-3 was an exception [ Figure 1 ]. Some individuals (1-082-3 and 1-233-3) also exhibited a high IgG titre but exhibited low neutralisation ability, and we propose that they were not protected against subsequent C. trachomatis infections. Similarly, in Western blot, there was a corresponding increase in IgG response observed among the individuals with high IgG titres [ Figure 1b ]. The individual infected with serovar K (only one patient was infected with serovar K, 1-049-3) also exhibited a high systemic antibody response, as well as high neutralising ability [60%; Figure 2 ], towards infections, and was not reinfected.
Systemic antibody responses of patients infected with Chlamydia trachomatis serovar E showed a disconnection between immune response and reinfection risk
The level of IgG and IgA antibodies as well as the in vitro neutralising ability was also analysed among the individuals (n = 12) infected with serovar E (analysed against serovar D).
The results showed that one of the individuals (infected with serovar E, 1-139-3) exhibited a high IgG titre (IgG) as well as a high neutralising (60%) ability and was not reinfected [ Figure 3 ]. Individuals 1-244-3 and 1-235-3, despite exhibiting a high IgG titre and high neutralising levels (63-70%), were still reinfected with Chlamydia. Individuals 1-103-3, 1-052-3, 1-202-3 and 1-010-3, exhibited a very high IgG titre but with low neutralising ability (5%-40%) towards infection and were found to become reinfected within 6-month study period [ Figure 3 ].
Systemic antibody responses of patients infected with Chlamydia trachomatis serovar F showed correlations with reinfection risk
The level of IgG and IgA antibodies as well as the in vitro neutralising ability was also analysed among the individuals (n = 4) infected with serovar F (analysed against serovar D). The results showed that individuals 1-124-3, 1-166-3 and 1-156-3 exhibited neither high IgG titre nor high neutralising (5%-36%) levels, and therefore, perhaps not surprisingly were reinfected, except 2-595-3 [ Figure 4 ].
The systemic antibody response of patients re-infected with Chlamydia trachomatis
Finally, we analysed the systemic antibody response among the individuals, who had repeated C. trachomatis IgG response was also observed among individuals infected with serovar F (1-124-15, 2-595-15) and analysed against D, these patients exhibited low neutralisation levels (<40%) towards infection [ Figure 8 ].
dIscussIon
C. trachomatis is the aetiological agent for the most prevalent bacterial STI in both developed and developing countries. The diagnostic rates for C. trachomatis infection have increased dramatically over the last decade. [19, 20] Repeated infections of C. trachomatis are very common and may represent reinfection from an untreated partner or treatment failure. [21] The individuals included in this relatively small study were studied over a 6-month period and any infection/ reinfection cases were included and recorded. The individuals were initially treated with a single oral dose of 1 g azithromycin at the time of recruitment into the ACTS trial, [17] subsequent to their diagnosis of their initial Chlamydia infection (infected with different Chlamydia . It has previously been reported that neutralising species-specific or serovar-specific antibodies can be produced in response to C. trachomatis infection in humans, as well as in some animal species. [21] Our results showed that a strong humoral immune response, as characterised by high serum antibody titres combined with high levels of in vitro neutralising antibodies (>60%) in serovars D and K, may have been associated with some level of protection against reinfections in these individuals. By comparison, some other individuals, also infected with serovar D, had low neutralisation capacity (<60%), and subsequently these individuals were reinfected, indicating no significant level of protection. This is in contrast to what was seen in some of the patients infected with serovar E, where individuals with a high neutralisation (40%-75%) capacity were still reinfected. This suggests subtle differences in epitopes between serovars D and E and this may relate to their in vivo protective ability. This study shows that individuals infected with serovars D or K exhibited a high systemic antibody response (IgG and IgA) as well as high neutralisation levels against serovar D except those individuals who were infected with serovar F. Individuals infected with serovars D and K showed an association with humoral immune response and reinfection risk (i.e., high immune response = low reinfection risk). Similarly, individuals infected with serovar F also showed an association with immune response and reinfection risk (i.e. low immune response = low reinfection risk). Although some of the individuals infected with serovar E exhibited a high systemic antibody response as well as high neutralisation level against tested serovar D, they showed disconnection between associations with humoral immune response and reinfection risk (i.e., a high immune response did not always result in protection from reinfection).
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